Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-7.51%
$3.98
0% positive prob.
5-Day Prediction
-18.85%
$3.49
0% positive prob.
20-Day Prediction
-21.63%
$3.37
0% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | SELL | -7.51% | -18.85% | -21.63% | 100.0% | Pending |
| Q2 2026 | SELL | -7.12% | -12.41% | +331.81% | 100.0% | Pending |
SEC 8-K filings with transcript text
Nov 9, 2026 · 100% conf.
1D
-7.51%
$3.98
Act: -21.18%
5D
-18.85%
$3.49
20D
-21.63%
$3.37
2 piii-20261109xexx991.htm
Document
Exhibit 99.1
P3 Health Partners Announces Third Quarter 2026 Results
Adjusted EBITDA of $21 Million for the Third Quarter and $101 Million Year-to-Date
Raises Full-Year 2026 Adjusted EBITDA Guidance Midpoint
Management to Host Conference Call and Webcast November 9, 2026 at 4:30 PM ET
HENDERSON, NV—November 9, 2026—P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the third quarter ended September 30, 2026.
“This was another strong quarter for P3. The foundation we have built over the past two years is showing up both in the care our patients receive and in the consistency of our results. We carry real momentum into 2027, as evidenced by our medical cost trend, and I am excited about what lies ahead for our patients, our providers, and our partners,” said Dr. Aric Coffman, CEO of P3.
Third Quarter 2026 Financial Results
•At-risk membership was approximately 105,000 members for the third quarter, a decrease of 9% compared to prior year, reflecting previously disclosed intentional network and payer rationalization. Total lives under management were approximately 133,500 for the quarter, including the approximately 28,000 lives under management service arrangements.
•Total revenue was $396 million, an increase of 15% compared with the prior year quarter. Total per-member capitated revenue increased 18% from the same period in the prior year driven by improved network economics, rate progression, and burden of illness performance.
•Medical margin(1) for the quarter was $43.9 million, or $140 on a per-member-per-month basis. The results include the favorable impact of payer settlements and prior year development recognized in the quarter. Excluding these items, medical margin for the quarter was $35.0 million, or $111 on a per-member-per-month basis.
•Net income was $30.8 million compared to net loss of $69.5 million in the prior year quarter.
•Adjusted EBITDA(1) for the quarter was $20.9 million, or $66 PMPM, compared to a loss of $45.9 million, or negative $132 per-member-per-month in the prior year quarter.
Revised Fiscal 2026 Guidance
•Full-year revised guidance reflects the increase to the low end of the Adjusted EBITDA range to $90 million, raising the midpoint to $100 million, based on underlying year-to-date performance, as well as the prior-year development and payer settlements recognized in the quarter.
Year Ending December 31, 2026
LowHigh
At-risk Members(2)
102,000106,000
Total Revenues (in millions)$1,525$1,600
Medical Margin(1)(3) (in millions) $260$300
Medical Margin(1)(3) PMPM $210$240
Adjusted EBITDA(1)(3) (in millions) $90$110
(1)Adjusted EBITDA, Adjusted EBITDA per member, per month (“PMPM”), medical margin, and medical margin PMPM are non-GAAP financial measures. For reconciliations of these measures to the most directly comparable GAAP measures, if applicable, and more information regarding the Company’s use of non-GAAP financial measures, please see the section titled “Non-GAAP Financial Measures.”
(2)See “Key Performance Metrics” for additional information on how the Company defines “at-risk members.”
(3) The Company is not able to provide a quantitative reconciliation of guidance for Adjusted EBITDA, medical margin and medical margin PMPM to net income (loss), gross profit and gross profit PMPM, the most directly comparable GAAP measures, respectively, and has not provided forward-looking guidance for net income (loss), because of the uncertainty around certain items that may impact net income (loss), gross profit (loss) or gross profit (loss) PMPM that are not within our control or cannot be reasonably predicted without unreasonable effort. For more information regarding the non-GAAP financial measures discussed in this press release, please see “Non-GAAP Financial Measures” below.
The foregoing 2026 outlook statement represents management's current estimate as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the “Cautionary Note Regarding Forward-Looking Statements” included in this release. Management does not assume any obligation to update these estimates.
Management to Host Conference Call and Webcast on November 9, 2026 at 4:30 PM ET
Title & Webcast P3 Health Third Quarter 2026 Earnings Conference Call
Date & Time November 9, 2026, 4:30 PM Eastern Time
Conference Call DetailsToll-Free 1-833-316-0546 (US)
International 1-412-317-0692 Ask to be joined into the P3 Health Partners call
The conference call will also be webcast live in the “Events & Presentations” section of the Investor page of the P3 website (ir.p3hp.org). The Company’s press release will be available on the Investor page of P3’s website in advance of the conference call. An archived recording of the webcast will be available
Aug 10, 2026 · 100% conf.
1D
-7.12%
$11.60
Act: -0.96%
5D
-12.41%
$10.94
20D
+331.81%
$53.93
Transcript text not available. View on SEC.gov →
May 14, 2026
Mar 26, 2026
Nov 14, 2025
Aug 14, 2025
May 15, 2025
Mar 27, 2025
Nov 12, 2024
Aug 7, 2024
May 8, 2024
Mar 28, 2024
Jan 10, 2024
Nov 8, 2023
Aug 7, 2023
May 10, 2023
Mar 31, 2023
Mar 15, 2023
Jan 11, 2023
Nov 14, 2022
This page provides P3 Health Partners Inc. (PIII) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on PIII's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.